Minoxidil was first used exclusively as an oral drug
Hair disorders cause psychological distress but
to treat high blood pressure.It was found to have
are generally poorly controlled. Minoxidil is very
the interesting side-effect of hair growth and
effective in frontal areas of the scalp, and also in
reversing baldness. Since 1988, Minoxidil has been
the vertex area in male-pattern hair loss. Typical
used for treating hair loss. The mechanism of
use level is from 2 to 5% in solution. Minoxidil is
action for Minoxidil is not known, as no other
the only proven hair loss treatment available
vasodilator has been shown to be effective in
treating hair loss. Recently, researchers at L’Oreal
Suggested that Minoxidil works by activating
PGHS 1 (prostaglandin endoperoxide synthase-1)
2,4-Diamino-6-piperidinopyrimidine-3-oxide
Soluble in ethanol ( 2%) & propylene glycol ( 7%),
Sparingly soluble in methanol, slightly soluble in
USA: OTC drug Europe: Annex II, Approved for use as an OTC drug
Japan: Quasi Drug Rest of the World: Approved for use in Australia and many Asian, South American and African countries.
Consult your regulatory authority for use level and restrictions.
As a drug to combat hair loss, the most common side effect is itchy scalp. Alcohol present in topical
preparations may dry the scalp, resulting in dandruff. In some cases Minoxidil may initially cause an increase in hair loss. This is called shedding and is seen as a long-term positive effect during hair loss treatment since the shedded hair strands will re-grow within a few months with renewed strength. There have been cases of allergic reactions to Minoxidil or the non-active ingredient propylene glycol, which
is found in some forms of topical Minoxidil. Large amounts of Minoxidil can cause hypotension, and it has been found that using petroleum jelly or tretinoin on the scalp with Minoxidil can cause too much of the drug absorption by the scalp, as can using the drug on sunburned scalps. If a person uses Minoxidil to stop hair loss for a length of time and then stops taking the drug, hair loss will occur again. Minoxidil is highly toxic to cats and can cause death when applied to their skin.
: Store in original, sealed container, avoid light and heat.
[1] Minoxidil - Substance Summary: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=7847484
[2] JF Michelet, S Commo, N Billoni, YF Mahe, BA Bernard, Activation of cytoprotective prostaglandin synthase-1 by Minoxidil as a possible explanation for its hair, growth-stimulating effect, J Invest Dermatol, 108(2):205-209, 1997.
[3] M Magerl, R Paus, N Farjo, S Müller-Röver, EM Peters, K Foitzik, DJ Tobin, Limitations of human occipital scalp hair follicle organ culture for studying the effects of minoxidil as a hair growth enhancer, Exp Dermatol, 13(10):635-42, 2004.
[4] OS Kwon, HK Pyo, YJ Oh, JH Han, SR Lee, JH Chung, HC Eun, KH Kim, Promotive effect of minoxidil combined with all-trans retinoic acid (tretinoin) on human hair growth in vitro, Journal of Korean medical science, 22(2):283-289, 2007.
[5] JC Kim, MD Kim, After-rinsing hair growth promotion of minoxidil-containing amino alpha-cyclodextrins, Journal of microbiology and biotechnology, 17(12):1965-1969, 2007.
[6] EA Olsen, D Whiting, W Bergfeld, J Miller, M Hordinsky, R Wanser, P Zhang, B Kohut, A multicenter, randomized,
placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology, 57(5):767-774, 2007.
[7] K. Shorter, NP Farjo, SM Picksley, and VA Randall, Human hair
The information given and the recommendations made herein are based on our research and literature search and are believed to be
accurate but no guarantee of their accuracy is made. This information is intended to be helpful, but no warranty is expressed or implied
as to the results obtained from use in the formulation, procedure or products suggested herein. Neither is any permission or
recommendation to practice any invention covered by patent either expressed or implied
sales_europe@kumarorganic.net Mobile: 00 65 9295 7034
Letters in Applied Microbiology ISSN 0266-8254Modified nitrocefin-EDTA method to differentially quantifythe induced L1 and L2 b-lactamases in StenotrophomonasmaltophiliaR.-M. Hu1, K.-H. Chiang2, C.-W. Lin2 and T.-C. Yang21 Department of Biotechnology and Bioinformatics, Asia University, Taichung, Taiwan2 Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichu